Wegovy sales double but Novo Nordisk sees slower sales growth in 2025
Wegovy maker Novo Nordisk on Wednesday forecast sales would grow at a slower rate this year although the outlook was roughly ...
Pharmaceutical Technology on MSN1d
Novo Nordisk plans new study for CagriSema, targets 2026 submission
CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...
Lost Money on Novo Nordisk A/S(NVO)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...
manilatimes2d
Novo Nordisk files annual report with the SEC
Bagsværd, Denmark, 5 February 2025 - Novo Nordisk A/S has filed its Annual Report 2024 on Form 20-F for the financial year ...
Novo Nordisk A/S Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - NVO
NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...
manilatimes13h
Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds ...
Traders Buy High Volume of Call Options on Novo Nordisk A/S (NYSE:NVO)
Novo Nordisk A/S (NYSE:NVO – Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Investors acquired 56,398 call options on the company. This represents an ...
Shareholder Rights Law Firm Robbins LLP Urges NVO Shareholders With Large Losses To Seek Counsel For The Novo Nordisk A/S Class Action
About Robbins LLP : A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LL have been dedicated to helping shareholders recover losses, improve corporate governance ...
Stocktwits on MSN9h
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars
Shares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 weight-loss drugs, Zepbound and Mounjaro, missed estimates for the second ...
Wegovy: sales of weight loss injection more than double
Wegovy: sales of weight loss injection more than double - The company said more than 45 million people were now ‘benefitting ...